A Phase II study of the standard therapy azacitidine (AZA) in combination with venetoclax (VEN) and tagraxofusp (TAG) in patients with high-risk chronic myelomonocytic leukemia (CMML).
Principal Investigator
Dott.ssa Elena Crisà
Contact Information for Access
Phase
FASE II
Status
ATTIVO
Objective of the study
The purpose of this study is to collect data on the tolerability, safety, and efficacy of azacitidine in combination with venetoclax and tagraxofusp in patients diagnosed with chronic myelomonocytic leukemia (
, CMML).
Pathologies
Onco-hematological (hematological cancers/malignancies)
Medication
Azacitidine: Antimetabolite
Venetoclax: BCL-2 inhibitor
Tagraxofusp: Anti-CD123 monoclonal antibody
Who is eligible to participate in the study?
Patients who are 18 years of age or older and who meet the study’s eligibility criteria may participate in this study.
Diagnosis of chronic myelomonocytic leukemia.
Back to search page